Wright Medical Group
This article was originally published in The Gray Sheet
Submission of a 510(k) application for the Arlington, Tennessee firm's Allomatrix products containing demineralized bone matrix is announced March 19. The submission responds to a recent "formal" notification from FDA, confirming a previous oral advisory that the products be regulated as medical devices, Wright says (1"The Gray Sheet" May 7, 2001, p. 17). No interruption in shipments is expected, according to Wright...
You may also be interested in...
CDRH's decision to require 510(k) submissions for demineralized bone matrix (DBM) products is at odds with previous policy statements by the Center for Biologics Evaluation & Research, the American Association of Tissue Banks maintains in comments sent to the FDA center directors April 19
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.